Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : A US National Health Care System? -- Ignore unavailable to you. Want to Upgrade?

To: TimF who wrote (8692)	8/26/2009 9:17:28 AM
From: Alastair McIntosh	Read Replies (1) \| Respond to of 42652

Doubling or tripling survival time is great, but unless the drug companies can charge for that benefit, it doesn't do a lot to motivate investment by them. Why would you think that a drug company wouldn't be able to charge for the benefit of doubling or tripling survival time? That is exactly what they can charge for. Health systems around the world are trying to make the best allocation of health care spending and cost-effectiveness is a major issue. The primary method of determining cost-effectiveness entails evaluating the cost for each year of survival offered by any drug or drug combination. If a new drug doubles survival time it can be priced considerably higher than current drugs.